Lieve Coenegrachts - Concepedia

Author

Lieve Coenegrachts

KU Leuven

Also Known As

Alexander Hein, Diether Lambrechts, Ingo Runnebaum, L. Coenegrachts, LIEVE COENEGRACHTS, Lieve Coenegrachts, Thilo Dörk

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

KU Leuven VIB-KU Leuven Center for Cancer Biology Universitair Ziekenhuis Leuven VIB-KU Leuven Center for Microbiology QIMR Berghofer Medical Research Institute

About

Lieve Coenegrachts is an author at KU Leuven specializing in medicine, tumor biology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	593
2	Engineering	2	2	185
3	Cell Biology	2	2	81
4	Health Sciences	1	1	50
5	Biomedical Engineering	1	1	112

Lieve Coenegrachts

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease Sara Van de Veire, Ingeborg Stalmans, Femke Heindryckx, Cell Ocular DiseaseEye DiseaseOphthalmologyPlgf InhibitionMedicine	2010	252
Increased skeletal VEGF enhances β‐catenin activity and results in excessively ossified bones Christa Maes, Steven Goossens, Sonia Bartunkova, The EMBO Journal	2009	198
In vitro study of the pulmonary translocation of nanoparticles Jorina Geys, Lieve Coenegrachts, Jo Vercammen, Toxicology Letters NanoparticlesEngineeringLung DepositionNanomaterialsPulmonary Translocation	2005	112
Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer Lorena Alonso‐Alconada, Laura Muinelo‐Romay, Kadri Madissoo, Molecular Cancer	2014	100
Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks Hui Zhao, Bernard Thienpont, Betül T. Yesilyurt, eLife GeneticsPathologyMismatch Repair DeficiencyDouble-strand BreaksTumor Biology	2014	86
High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma Diego A. Garcia-Dios, Diether Lambrechts, Lieve Coenegrachts, Gynecologic Oncology EngineeringMedicinePathologyTp53 MutationsCancer Genomics	2012	73
Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies Jeroen Depreeuw, Els Hermans, Stefanie Schrauwen, Gynecologic Oncology Tumor BiologyPreclinical EvaluationMedicineGynecologyGynecology Oncology	2015	53
Anti–Placental Growth Factor Reduces Bone Metastasis by Blocking Tumor Cell Engraftment and Osteoclast Differentiation Lieve Coenegrachts, Christa Maes, Sophie Torrekens, Cancer Research OsteoporosisTumor BiologyAngiogenesisBone Morphogenic ProteinFibroblast Growth Factor	2010	50
Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas Lieve Coenegrachts, Diego A. Garcia-Dios, Jeroen Depreeuw, Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin Tumoral PathologySomatic VariantSerous CarcinomasMedicinePathology	2015	36
Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models Stefanie Schrauwen, Jeroen Depreeuw, Lieve Coenegrachts, Gynecologic Oncology OncologyMedicineInhibit GrowthGynecologyCancer Growth	2015	31

Page 1